Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Dupixent Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Dupixent (dupilumab) prior authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria and reauthorization requirements for Dupixent (dupilumab) for multiple diagnoses including allergic fungal rhinosinusitis, atopic dermatitis, asthma, bullous pemphigoid, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria for CareOregon members.

    Policy Summary
    Payercareoregon
    PolicyDupixent (dupilumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic confirmation, specialist involvement, and documentation of prior therapy failures.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial approval length
    12 monthsreauthorization length
    ≥6 yrsAFRS min age
    ≥12 yrsCSU min age
    BEC ≥150

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    COPD eosinophil threshold

    Coverage Criteria by Indication

    AFRS Initial Authorization

    Covered when ALL of the following are met for Allergic Fungal Rhinosinusitis (initial authorization):

    AFRS Initial: Member is at least 6 years old
    AFRS Diagnostic: Diagnosis of allergic fungal rhinosinusitis confirmed by CT scan AND two of the following: IgE-mediated inflammatory response to fungal hyphae; sensitization to fungus by skin testing; positive fungal-specific IgE in serum; positive fungal stain of nasal contents removed during surgery
    AFRS Surgery History: Documented history of sinonasal surgery related to AFRS (e.g., functional endoscopic sinus surgery)
    AFRS Prior Therapy: Failure of (or contraindication to) two intranasal corticosteroids (e.g., fluticasone, budesonide)
    AFRS Dosing: Dupixent will be dosed every other week

    AFRS Reauthorization

    AFRS reauthorization criteria:

    AFRS Reauth: Documented clinically significant improvement in sinonasal symptoms (e.g., nasal obstruction, congestion, discharge, facial pressure/pain); decreased need for intranasal or systemic corticosteroids; and/or reduced risk of needing surgery

    Atopic Dermatitis Initial Authorization

    Atopic dermatitis initial authorization criteria (pediatric and adult pathways):

    Atopic Dermatitis Initial: Either: (A) Member under 21 AND diagnosis of chronic, moderate-to-severe atopic dermatitis (≥10% BSA or involvement of hand, foot, face, or mucous membranes) with functional impairment AND failure of a combination of steroid and nonsteroid topical medications; OR (B) Diagnosis of chronic, moderate-to-severe atopic dermatitis with functional impairment AND failure of two of the following: combination of steroid and nonsteroid topical medications, an oral DMARD (e.g., methotrexate or cyclosporine), or phototherapy
    Atopic Dermatitis Dosing: Dupixent will be dosed every other week

    Atopic Dermatitis Reauthorization

    Atopic dermatitis reauthorization criteria:

    Atopic Dermatitis Reauth: Member experienced a 50% reduction in eczema and/or there is evidence of significant functional improvement

    Asthma Initial Authorization

    Asthma initial authorization criteria:

    Asthma Prescriber: Prescribed by a pulmonologist
    Asthma Diagnosis: Diagnosis of severe asthma uncontrolled despite treatment with high-dose inhaled corticosteroid plus long-acting beta agonist, leukotriene inhibitor (e.g., montelukast), and long-acting muscarinic antagonist
    Asthma Phenotype: Either: eosinophilic phenotype with frequent exacerbations and eosinophil count ≥150/mcL within the past 6 months; OR oral corticosteroid–dependent asthma requiring oral steroids to maintain control≥ 150/mcL within the past 6 months

    Asthma Reauthorization

    Asthma reauthorization criteria:

    Asthma Reauth: Member had reduction in asthma exacerbations or decrease in oral corticosteroid dose and demonstrated sustained clinical improvement from baseline

    Bullous Pemphigoid Initial Authorization

    Bullous pemphigoid initial authorization criteria:

    Bullous Prescriber: Prescribed by a dermatologist
    Bullous Diagnosis: Histopathologic (biopsy) diagnosis of bullous pemphigoid
    Bullous Prior Therapy: Failure of a 3-month trial of azathioprine, methotrexate, or mycophenolate OR contraindication to all three
    Bullous Steroid Failure: Failure of oral corticosteroids (steroids failed to improve pruritus, improve current lesions, or prevent new lesions)
    Bullous Concomitant: Concomitant oral corticosteroid therapy has been prescribed for use with Dupixent

    Bullous Pemphigoid Reauthorization

    Bullous pemphigoid reauthorization criteria:

    Bullous Reauth: Member demonstrated significant improvement compared to baseline (e.g., improvement in pruritus, healing of lesions, or ability to taper systemic corticosteroids) and provider determines continued use is medically necessary

    CRSwNP Initial Authorization

    Chronic rhinosinusitis with nasal polyps initial authorization criteria:

    CRSwNP Prescriber: Prescribed by an allergist or ENT
    CRSwNP Surgery History: Member has recurrent nasal polyps after multiple prior sinus surgeries within the past 2 years
    CRSwNP Prior Therapy: Failure of all the following: at least 2 prior intranasal corticosteroids AND Sinuva; member is currently adherent to a nasal corticosteroid
    CRSwNP Surgical Risk: Member is at risk of another sinus surgery AND provider provided statement why sinus surgery is not medically appropriate

    CRSwNP Reauthorization

    CRSwNP reauthorization criteria:

    CRSwNP Reauth: Member had clinically significant improvement in symptoms and reduced risk of needing surgery

    Chronic Spontaneous Urticaria Initial Authorization

    Chronic spontaneous urticaria initial authorization criteria:

    CSU Diagnosis: Diagnosis of chronic spontaneous urticaria with hives and/or angioedema for ≥6 weeks
    CSU Severity: Severe disease necessitating medical treatment with BOTH: at least 50 wheals or large confluent wheals, AND itching impacting sleep or daily activities
    CSU Age: Member is at least 12 years of age
    CSU Prescriber: Prescribed by or in consultation with an allergist/immunologist or otolaryngologist
    CSU Prior Therapy: Failure of all of the following: at least two second-generation antihistamines; an antihistamine at a higher-than-normal dose (e.g., cetirizine 20 mg daily); montelukast; either hydroxyzine or an H2 antagonist (e.g., famotidine or cimetidine); and prior trial of omalizumab (Xolair) with pre-approval

    Chronic Spontaneous Urticaria Reauthorization

    Chronic spontaneous urticaria reauthorization criteria:

    CSU Reauth: Member had significant improvement in the condition with at least one of the following: decrease in wheals and/or angioedema; improvement in sleep and/or ability to participate in daily activities; AND provider documented that continued treatment is medically necessary and it is not appropriate to taper and stop therapy at this time

    Chronic Spontaneous Urticaria — Initial Authorization

    Covered when ALL of the following are met

    CSU initial: 1) Diagnosis of chronic spontaneous urticaria with hives and/or angioedema >=6 weeks; 2) Severe disease necessitating treatment with BOTH: at least 50 wheals or large confluent wheals, AND itching impacting sleep or daily activities; 3) Member is at least 12 years of age; 4) Prescribed by or in consultation with an allergist/immunologist or otolaryngologist; 5) Failure of ALL of the following: two second-generation antihistamines, an antihistamine at higher-than-normal dose (e.g., cetirizine 20 mg daily), montelukast, either hydroxyzine or an H2 antagonist (e.g., famotidine or cimetidine), and prior Xolair (omalizumab) with pre-approval

    Approval length: 6 months for initial authorization

    Chronic Spontaneous Urticaria — Reauthorization

    Covered when ALL of the following are met

    CSU reauth: 1) Member had significant improvement in symptoms (decrease in wheals and/or angioedema OR improvement in sleep/ability to participate in activities); 2) Provider documents continued medical necessity and that tapering/stopping therapy is not appropriate at this time

    Approval length: 12 months for reauthorization

    COPD with Chronic Bronchitis — Reauthorization

    Covered when ALL of the following are met

    COPD reauth: 1) Prescribed by a pulmonologist; 2) Diagnosis of COPD with chronic bronchitis; 3) Blood eosinophil count >=150 cells/mcL within past 3 months; 4) History of at least 2 moderate or 1 severe COPD exacerbation in last year despite adherence to inhaled LABA+LAMA+ICS triple therapy; 5) Member had clinical improvement in symptoms and/or reduction in frequency or severity of exacerbations

    Approval length: 12 months for reauthorization

    Eosinophilic Esophagitis — Initial and Reauthorization

    Covered when ALL of the following are met

    EoE initial: 1) Prescribed by a gastroenterologist; 2) Diagnosis of eosinophilic esophagitis confirmed by imaging; 3) For initial authorization: member had clinical improvement in symptoms

    Initial approval length 6 months; reauthorization 12 months

    Prurigo Nodularis — Initial and Reauthorization

    Covered when ALL of the following are met (criteria differ by age group)

    Prurigo nodularis initial under 21: All of the following: member is under age 21; diagnosis of chronic, moderate to severe prurigo nodularis (>=10% BSA or involvement of hand/foot/face/mucous membranes) with functional impairment; failure of combination of steroid and nonsteroid topical medications

    Initial approval length 6 months for PN

    Prurigo nodularis initial 21 and older: Member 21 years or older; diagnosis of chronic, moderate to severe prurigo nodularis (>=10% BSA or involvement of hand/foot/face/mucous membranes) with functional impairment; failure of two of the following: combination of steroid and nonsteroid topical medications, an oral DMARD (e.g., methotrexate or cyclosporine), phototherapy
    PN reauth: Member had significant response to therapy (reduction in number of nodules, significant decrease in pruritus, and/or functional improvement)

    Reauthorization approval length 12 months

    This section summarizes the coverage criteria for Chronic Spontaneous Urticaria (CSU)≥ 6 weeks, that disease is severe (for example, ≥50 wheals or large confluent wheals and pruritus that impacts sleep or daily activities), and that the request is prescribed by or in consultation with an allergist/immunologist or otolaryngologist. The member must be at least 12 years of age to meet initial authorization criteria.

    Prior therapy requirements must be clearly documented. For CSU initial approval, the member must have failed all of the following: two second‑generation antihistamines, an antihistamine at a higher‑than‑normal dose (e.g., cetirizine 20 mg daily), montelukast, either hydroxyzine or an H2 antagonist (such as famotidine or cimetidine), and prior trial of omalizumab (Xolair) with pre‑approval. Reauthorization requires documentation of significant clinical improvement (for example, decreased wheals/angioedema or improved sleep/ability to participate) and a provider statement that continued therapy is medically necessary and tapering/stopping is not appropriate.

    Approval lengths are indication‑specific: initial authorization for CSU is typically 6 months, and reauthorization approval length is typically 12 months. Requests should include objective documentation of prior therapy trials, disease duration, severity measures, and specialist involvement to support medical necessity.

    No additional exclusions or not‑medically‑necessary (NMN) conditions are listed in the provided CSU excerpt. Reviewers should rely on the explicit criteria above; absence of required documentation (for example, missing prior therapy trials or lack of documentation of ≥6 weeks of disease) may lead to denial.

    Initial Therapy Requirements

    Initial therapy

    Initial authorization criteria vary by indication and require specialist involvement, diagnostic confirmation, and prior therapy failures as detailed per indication.

    Initial Therapy General: Dupixent dosing will be every other week for many indications unless otherwise specified; specialist prescriber requirements apply for certain diagnoses

    Initial therapy requirements

    Initial authorization criteria per indication

    CSU initial: See chronic spontaneous urticaria initial authorization criteria: diagnosis >=6 weeks, severe disease features, age >=12, specialty prescriber, failure of specified prior therapies
    EoE initial: Prescribed by gastroenterologist; diagnosis confirmed by imaging; member had clinically significant improvement in symptoms

    Reauthorization / Continuation Requirements

    Reauthorization requirements

    Reauthorization generally requires documented clinical improvement and provider attestation that continued therapy is medically necessary and tapering is not appropriate.

    General Reauth: Documented clinical improvement appropriate to indication (e.g., reduced exacerbations for asthma, symptom improvement for CRSwNP/AFRS, reduction in eczema or pruritus for dermatologic conditions) and provider documents continued medical necessity

    Continuation/Reauthorization criteria

    Reauthorization requires documented clinical benefit and provider statement that continued therapy is medically necessary and not appropriate to stop

    CSU continuation: Member had significant improvement in symptoms and provider documents continued medical necessity (tapering/stopping not appropriate)
    EoE continuation:

    Required Prior Therapy Trials

    Indication / StepRequired prior trials or criteria
    Allergic Fungal Rhinosinusitis (AFRS)
    Failure of (or contraindication to) two intranasal corticosteroids (e.g., fluticasone, budesonide); plus CT-confirmed AFRS with two supporting findings and history of sinonasal surgery required per AFRS criteria
    Atopic Dermatitis (moderate-to-severe)
    Failure of combination steroid and nonsteroid topical medications; OR failure of two of the following: combination topical therapy, an oral DMARD (e.g., methotrexate or cyclosporine), or phototherapy
    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    Failure of at least 2 prior intranasal corticosteroids and Sinuva; member must be adherent to a nasal corticosteroid and have recurrent polyps after multiple sinus surgeries (prescribed by allergist or ENT)
    Other indications (select dermatologic, pulmonary, GI conditions)
    Initial authorization criteria vary by indication but generally require specialist prescriber, diagnostic confirmation where applicable, and documented failure of listed prior therapies (see indication-specific criteria)
    CSU StepRequired prior therapies (must try and fail)
    Ordered sequence required before Dupixent for chronic spontaneous urticaria (CSU)
    Failure of ALL of the following: at least two second‑generation antihistamines (e.g., loratadine, cetirizine); an antihistamine at higher-than-normal dose (e.g., cetirizine 20 mg daily); montelukast; either hydroxyzine or an H2 antagonist (e.g., famotidine or cimetidine); and prior trial of Xolair (omalizumab) with pre-approval

    Clinical Thresholds and Key Values

    inv-22: eosinophil count — ≥ 150/mcL within the past 6 months
    Eosinophil threshold (asthma)≥ 150/mcL within the past 6 months
    ContextUsed to identify eosinophilic asthma phenotype for Dupixent initial authorization when combined with frequent exacerbations
    Supporting requirementMust be documented in chart/lab results within past 6 months
    inv-23: disease duration for CSU — ≥ 6 weeks
    CSU disease duration>= 6 weeks
    DefinitionPresence of hives and/or angioedema for greater than or equal to 6 weeks qualifies as chronic spontaneous urticaria
    Documentation

    What Providers Must Do

    Prior Authorization

    Prior authorization required; typical approval lengths

    Prior authorization is required for Dupixent. Initial approvals are typically 6 months for many indications; reauthorization approval lengths are generally 12 months for certain diagnoses.

    Prior Authorization

    Specialist prescriber required for specific indications

    Certain indications require that Dupixent be prescribed by a relevant specialist (examples in the policy include allergist/immunologist, ENT, pulmonologist, dermatologist, or gastroenterologist).

    Prior Authorization

    PA required for Dupixent in chronic spontaneous urticaria (CSU)

    Prior authorization is required for Dupixent for chronic spontaneous urticaria (CSU); initial approval requires meeting CSU clinical criteria and specialist involvement, and reauthorization requires documented significant improvement.

    Background

    Dupilumab is an interleukin‑4/interleukin‑13 pathway–targeting monoclonal antibody indicated for multiple allergic and inflammatory conditions. This policy defines indication‑specific authorization and reauthorization requirements — including diagnostic confirmation, documented trials of prior therapies, specialist prescriber requirements, age and laboratory thresholds, and evidence of clinical improvement — that must be met for coverage of Dupixent.

    Definitions and Clinical Terms

    inv-47: AFRS — Allergic Fungal Rhinosinusitis requiring CT confirmation plus two supportive findings (e.g., fungal-specific IgE, positive fungal stain).
    AFRS diagnostic confirmationCT-confirmed allergic fungal rhinosinusitis plus TWO supportive findings (e.g., IgE-mediated response to fungal hyphae, sensitization by skin testing, positive fungal-specific IgE, or positive fungal stain)
    Surgical historyDocumented history of sinonasal surgery related to AFRS (e.g., functional endoscopic sinus surgery) is required
    Prior therapyFailure of (or contraindication to) two intranasal corticosteroids is required prior to approval
    inv-48: Chronic spontaneous urticaria — Defined as hives and/or angioedema for ≥6 weeks with significant disease burden impacting sleep or daily activities.
    CSU definitionHives and/or angioedema present for ≥6 weeks with significant disease burden impacting sleep or daily activities
    Policy Summary
    Payercareoregon
    PolicyDupixent (dupilumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic confirmation, specialist involvement, and documentation of prior therapy failures.
    SourceLink
    On This Page
    Coverage Criteria by IndicationInitial Therapy RequirementsReauthorization / Continuation RequirementsRequired Prior Therapy TrialsClinical Thresholds and Key ValuesWhat Providers Must DoBackgroundDefinitions and Clinical Terms
    PN initial: Age-based criteria; under 21: diagnosis with functional impairment and failure of topical combination; 21+: diagnosis with functional impairment and failure of two specified systemic/topical/phototherapy options
    Member had clinically significant improvement in symptoms
    PN continuation: Member had significant response in therapy (reduced nodules, decreased pruritus, functional improvement)
    Provider must document duration in medical record for initial authorization
    inv-24: Age and lab thresholds — CSU: >= 12 years of age; COPD: BEC >= 150 cells/mcL within past 3 months
    CSU minimum age>= 12 years of age
    COPD BEC thresholdBlood eosinophil count (BEC) >= 150 cells/mcL within the past 3 months
    Use in criteriaAge and lab thresholds are required documentation elements for CSU and COPD reauthorization respectively
    inv-25: CSU disease duration — >= 6 weeks
    CSU disease duration (repeat)>= 6 weeks
    Clinical implicationDuration requirement confirms chronicity for initial authorization of Dupixent in CSU
    Source noteMust be documented in initial request per policy criteria
    inv-50: Blood eosinophil count (BEC) threshold for COPD — BEC >= 150 cells/mcL within the past 3 months required for COPD with chronic bronchitis indication.
    BEC threshold for COPD (reauthorization)BEC >= 150 cells/mcL within the past 3 months
    IndicationRequired for COPD with chronic bronchitis indication for Dupixent reauthorization
    DocumentationLaboratory result must be available in medical record within prior 3 months
    • Initial approval length: 6 months
    • Reauthorization approval length: 12 months
    • Prescribed by or in consultation with an allergist/immunologist or otolaryngologist
    Prior Authorization

    PA required for Dupixent in COPD with chronic bronchitis

    Prior authorization is required for Dupixent for COPD with chronic bronchitis for reauthorization; approval requires documentation of blood eosinophil count, exacerbation history despite triple inhaled therapy, specialist prescriber, and clinical improvement.

    • Prescribed by a pulmonologist
    • Blood eosinophil count ≥150 cells/mcL within past 3 months
    • History of ≥2 moderate or ≥1 severe COPD exacerbation in last year despite LABA+LAMA+ICS
    • Reauthorization approval length: 12 months
    Prior Authorization

    PA required for Dupixent in EoE and prurigo nodularis

    Prior authorization is required for Dupixent for eosinophilic esophagitis (EoE) and prurigo nodularis (PN); approvals require specialist prescribing and diagnostic confirmation specific to each condition.

    • EoE: prescribed by a gastroenterologist and diagnosis confirmed by imaging (initial approval 6 months; reauth 12 months)
    • PN: age-based criteria and required prior therapy trials (initial approval 6 months)
    Step Therapy

    AFRS step therapy: intranasal corticosteroid trials required

    For Allergic Fungal Rhinosinusitis (AFRS), approval requires failure of (or contraindication to) two intranasal corticosteroids prior to Dupixent.

    • Examples: fluticasone, budesonide
    Step Therapy

    Atopic dermatitis step therapy: topical then systemic options

    For atopic dermatitis, prior authorization requires failure of topical steroid and nonsteroid topical therapy; alternatively, failure of two systemic/other options (e.g., an oral DMARD such as methotrexate or cyclosporine, or phototherapy) is required for certain pathways.

    • Pediatric/adult pathways specify combination topical failure or two systemic/other therapy failures
    • Dupixent dosing: every other week
    Step Therapy

    CRSwNP step therapy: intranasal corticosteroids, Sinuva, and surgical history required

    For chronic rhinosinusitis with nasal polyps (CRSwNP), approval requires failure of at least two intranasal corticosteroids and Sinuva, evidence of recurrent polyps/surgery, and adherence to nasal corticosteroid therapy.

    • Prescribed by an allergist or ENT
    • Recurrent nasal polyps after multiple prior sinus surgeries within past 2 years
    • Member must be adherent to nasal corticosteroid
    Step Therapy

    CSU step therapy: required sequence of antihistamines, montelukast, H2/hydroxyzine, and Xolair

    For chronic spontaneous urticaria (CSU), approval requires documented failure of at least two second‑generation antihistamines, a high‑dose antihistamine trial, montelukast, either hydroxyzine or an H2 antagonist, and prior omalizumab (Xolair) with pre‑approval.

    • Examples: loratadine, cetirizine (two second‑generation antihistamines)
    • High‑dose trial example: cetirizine 20 mg daily
    • H2 antagonists examples: famotidine, cimetidine
    • Xolair (omalizumab) must have been tried with pre‑approval
    Step Therapy

    Required prior therapy sequence for CSU before Dupixent

    Before Dupixent for CSU, the patient must have failed an ordered sequence of therapies: two second‑generation antihistamines, a higher‑than‑normal dose antihistamine trial, montelukast, hydroxyzine or an H2 antagonist, and prior trial of omalizumab (Xolair) with pre‑approval.

    • Failure of all listed therapies is required for initial authorization
    • Initial approval length: 6 months
    Documentation Required

    AFRS documentation: CT confirmation + two supportive findings and surgery history

    For AFRS, documentation must include CT-confirmed diagnosis plus two supportive findings (such as IgE‑mediated response to fungal hyphae, positive fungal‑specific IgE, or positive fungal stain) and a history of sinonasal surgery.

    • Supportive findings examples: IgE mediated inflammatory response to fungal hyphae; sensitization by skin testing; positive fungal‑specific IgE in serum; positive fungal stain of nasal contents
    • Documented history of sinonasal surgery (e.g., functional endoscopic sinus surgery)
    Documentation Required

    Asthma documentation: phenotype, eosinophil count, exacerbations, and controller trials

    For asthma, documentation must show the prescribing pulmonologist confirms severe or eosinophilic phenotype, a history of frequent exacerbations, an eosinophil count ≥150/mcL within the past 6 months, and prior controller therapy trials (high‑dose ICS/LABA plus additional controllers).

    • Prescribed by a pulmonologist
    • Eosinophil count ≥150/mcL within past 6 months
    • Prior treatment with high‑dose inhaled corticosteroid + LABA, leukotriene inhibitor, and LAMA
    Documentation Required

    Bullous pemphigoid documentation: biopsy and prior immunosuppressant/corticosteroid trials

    For bullous pemphigoid, documentation must include a biopsy‑confirmed diagnosis and evidence of failure of (or contraindication to) listed immunosuppressants (azathioprine, methotrexate, mycophenolate) and failure of oral corticosteroids.

    • Prescribed by a dermatologist
    • Histopathologic (biopsy) diagnosis required
    • Failure of a 3‑month trial of azathioprine, methotrexate, or mycophenolate or contraindication to all
    Documentation Required

    Required documentation for CSU: duration, severity, age, specialist, and prior therapies

    For CSU initial authorization, document disease duration (≥6 weeks), severity (wheal count and impact on sleep/activities), age (≥12 years), specialist involvement, and all required prior medication trials including omalizumab pre‑approval.

    • Diagnosis: hives and/or angioedema ≥6 weeks
    • Severity: ≥50 wheals or large confluent wheals and itching impacting sleep or daily activities
    • Prescribed by or in consultation with an allergist/immunologist or otolaryngologist
    • Prior therapies: two second‑generation antihistamines; high‑dose antihistamine; montelukast; hydroxyzine or H2 antagonist; Xolair with pre‑approval
    Documentation Required

    Required documentation for COPD: recent BEC, exacerbation history, and pulmonologist prescriber

    For COPD reauthorization, document a recent blood eosinophil count (within 3 months) ≥150 cells/mcL, history of exacerbations despite adherence to triple inhaled therapy (LABA+LAMA+ICS), and that the prescriber is a pulmonologist.

    • Blood eosinophil count ≥150 cells/mcL within past 3 months
    • History of ≥2 moderate or ≥1 severe COPD exacerbation in last year despite adherence to inhaled LABA+LAMA+ICS
    • Prescribed by a pulmonologist
    Documentation Required

    Required documentation for EoE: diagnostic confirmation and gastroenterologist prescriber

    For eosinophilic esophagitis (EoE), document diagnosis confirmation by endoscopy/biopsy or imaging and that the prescriber is a gastroenterologist.

    • Prescribed by a gastroenterologist
    • Diagnosis of eosinophilic esophagitis confirmed by imaging (e.g., endoscopy/biopsy as indicated in policy)
    Denial Risk

    Denial risk: missing AFRS diagnostic confirmation

    AFRS requests lacking CT confirmation plus two supportive findings (and surgery history) may be denied for failure to meet diagnostic confirmation requirements.

    • Required supportive findings examples: fungal‑specific IgE, positive fungal stain, skin testing, IgE‑mediated response
    Denial Risk

    Denial risk: missing asthma phenotype testing or controller therapy history

    For asthma, absence of a documented eosinophil count ≥150/mcL within the past 6 months, lack of prior controller therapy documentation, or missing exacerbation history may trigger denial.

    • Eosinophil threshold: ≥150/mcL within past 6 months
    • Prior controller therapies required: high‑dose ICS/LABA plus leukotriene inhibitor and LAMA
    • Evidence of frequent exacerbations (urgent care/ED visits or hospitalization) required
    Denial Risk

    Denial risk: missing required prior therapies for CSU

    Failure to document required prior trials for CSU—such as two second‑generation antihistamines, a high‑dose antihistamine trial, and montelukast—may result in denial of Dupixent.

    • Required prior therapies include: two second‑generation antihistamines; antihistamine at higher‑than‑normal dose (e.g., cetirizine 20 mg); montelukast; hydroxyzine or H2 antagonist; prior Xolair (omalizumab) with pre‑approval
    Denial Risk

    Denial risk: COPD eligibility not documented (BEC or exacerbation history)

    For the COPD indication, lack of documentation of a blood eosinophil count ≥150 cells/mcL within the past 3 months or insufficient exacerbation history (at least 2 moderate or 1 severe in the past year despite LABA+LAMA+ICS) may lead to denial.

    • BEC threshold: ≥150 cells/mcL within past 3 months
    • Exacerbation history required: ≥2 moderate or ≥1 severe in last year despite adherence to triple inhaled therapy
    Severity features
    May include large confluent wheals and pruritus affecting sleep or participation in daily activities
    Prescriber requirementPrescribed by or in consultation with an allergist/immunologist or otolaryngologist
    inv-49: Chronic spontaneous urticaria (CSU) — Presence of hives and/or angioedema for >= 6 weeks with severe disease features such as >=50 wheals or pruritus impact.
    CSU diagnostic criteria (severe)Presence of hives and/or angioedema for >= 6 weeks plus severe features such as at least 50 wheals or large confluent wheals and itching that impacts sleep or daily activities
    Age requirementMember must be at least 12 years of age for this indication
    Prior therapy requirementFailure of specified prior therapies including two second-generation antihistamines, high-dose antihistamine trial, montelukast, hydroxyzine or H2 antagonist, and prior omalizumab (with pre-approval)
    inv-50: Blood eosinophil count (BEC) threshold for COPD — BEC >= 150 cells/mcL within the past 3 months required for COPD with chronic bronchitis indication.
    COPD BEC threshold (repeat)BEC >= 150 cells/mcL within the past 3 months
    PurposeRequired element for COPD with chronic bronchitis reauthorization to demonstrate eosinophilic phenotype
    Associated requirementsAlso requires history of exacerbations despite adherence to LABA+LAMA+ICS and pulmonologist involvement